About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Philadelphia | 20,904 Studies Near You | Clareo Health

Clinical Trials LocationsPhiladelphia

Clinical Trials in Philadelphia

Discover 20,904 clinical trials near Philadelphia, Pennsylvania. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 11661-11680 of 20,904 trials

COMPLETEDPhase 2< 1 mile

Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair

NCT00485433

The purpose of this study is to evaluate three dose levels of SKY0402 compared with 105 mg of bupivacaine HCl.

Postoperative Pain

Pacira Pharmaceuticals, Inc98 participantsStarted Jun 2007

Arcadia, California, United States • Laguna Hills, California, United States • Pasadena, California, United States +4 more locations

COMPLETEDPhase 2< 1 mile

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT02413372

The purpose of this study is to determine whether BMS-986036 is effective in the treatment of subjects with Non-alcoholic Steatohepatitis (NASH).

Non-Alcoholic Steatohepatitis

Bristol-Myers Squibb184 participantsStarted May 2015

Rialto, California, United States • San Diego, California, United States • Indianapolis, Indiana, United States +14 more locations

Find Trials by Condition in Philadelphia

Breast Cancerin Philadelphia Lung Cancerin Philadelphia Prostate Cancerin Philadelphia Colorectal Cancerin Philadelphia Melanomain Philadelphia Leukemiain Philadelphia Lymphomain Philadelphia Pancreatic Cancerin Philadelphia Ovarian Cancerin Philadelphia Brain Cancerin Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2< 1 mile

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT03400163

The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

Bristol-Myers Squibb3 participantsStarted May 2015

Philadelphia, Pennsylvania, United States • San Antonio, Texas, United States

TERMINATEDNA< 1 mile

Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents

NCT04089761

Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. This is a prospective, single arm, open label, multicenter trial of the safety and efficacy of Nerivio™ for the acute treatment of migraine in adolescents The study will be conducted in three phases: Phase I - Run-in: Phase II - Treatment phase: Phase III (optional) - Free-use

Theranica60 participantsStarted Oct 2019

Aurora, Colorado, United States • Hialeah, Florida, United States • Miami, Florida, United States +9 more locations

COMPLETEDPhase 114 miles

Safety and Tolerability of PNT001 in Healthy Adults

NCT04096287

This first in human study is a multi-center, randomized, double-blind, placebo-controlled single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of intravenous PNT001 in healthy adult participants.

Pinteon Therapeutics, Inc49 participantsStarted Sep 2019

Rogers, Arkansas, United States • San Diego, California, United States • Marlton, New Jersey, United States +1 more locations

COMPLETEDEARLY Phase 136 miles

Buccal Versus Vaginal Misoprostol In Combination With Foley Bulb

NCT03976037

Combined misoprostol and Foley bulb catheter has been shown to be an effective induction method. However, optimal route of administration for misoprostol has not been established. Therefore, the purpose of this study is to compare the effectiveness and safety of combination buccal miso-foley to combination vaginal miso-foley for third trimester cervical ripening and induction of labor.

Induction of Labor

Christiana Care Health Services216 participantsStarted Jun 2019

Newark, Delaware, United States

COMPLETEDPhase 336 miles

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

NCT03061812

The purpose of this randomized, open-label, 2-arm, phase 3 study is to assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic SCLC with high levels of DLL3, who have first disease progression during or following front-line platinum-based chemotherapy.

Small Cell Lung Cancer

AbbVie444 participantsStarted Apr 2017

Huntsville, Alabama, United States • Mobile, Alabama, United States • Little Rock, Arkansas, United States +192 more locations

TERMINATEDPhase 248 miles

Efficacy and Safety of Atacicept in IgA Nephropathy

NCT02808429

This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The study hypothesis was that treatment with Atacicept would reduce proteinuria compared to placebo.

IgA Nephropathy

EMD Serono Research & Development Institute, Inc.16 participantsStarted Jan 2017

Glendale, Arizona, United States • Chula Vista, California, United States • Denver, Colorado, United States +15 more locations

TERMINATEDPhase 253 miles

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT01129024

The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.

Immune Thrombocytopenia

Shionogi19 participantsStarted Apr 2010

Anaheim, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +16 more locations

COMPLETEDPhase 1/263 miles

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

NCT02697591

This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts. Part 1 is dose escalation and safety expansion which determines the optimal dose and maximum number of tolerated doses. Part 2 is dose expansion in which Part 1 recommended dose will be evaluated.

Advanced MalignanciesMetastatic Cancer

Incyte Biosciences International Sàrl100 participantsStarted Jun 2016

Los Angeles, California, United States • New Haven, Connecticut, United States • Boston, Massachusetts, United States +5 more locations

COMPLETEDPhase 480 miles

Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.

NCT00290901

This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.754 participantsStarted Mar 2006

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +51 more locations

COMPLETEDNA81 miles

Automated Graduated CPAP (AGPAP) for Improved Adherence in Newly Diagnosed Obstructive Sleep Apnea (OSA) Patients

NCT01450540

Although positive airway pressure (PAP) is a highly effective treatment for sleep apnea, adherence to therapy remains an obstacle. Automated Graduated CPAP (AGPAP), also know as EZ-start, is an extended duration ramp, where the patient receives pressure below their prescription during an acclimation phase. The algorithm gradually increases pressure to therapy level based on usage. The aim of this study was to determine the effectiveness of the AGPAP acclimation period and its impact on short term adherence.

Obstructive Sleep Apnea

Philips Respironics241 participantsStarted Sep 2011

Colorado Springs, Colorado, United States • Atlanta, Georgia, United States • St Louis, Missouri, United States +2 more locations

WITHDRAWNPhase 281 miles

Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma

NCT04526080

The primary goal of this study is to gather efficacy data concerning overall survival with electromagnetic field when compared to a placebo amplitude-modulated radiofrequency electromagnetic field device in subjects who have failed or are intolerant to at least two previous systemic therapies

Hepatocellular Carcinoma

Wake Forest University Health SciencesStarted Apr 2021

Chicago, Illinois, United States • New York, New York, United States • Winston-Salem, North Carolina, United States

COMPLETEDPhase 181 miles

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

NCT02897765

The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a substantial improvement over other available therapies such as nivolumab alone. All eligible patients will receive NEO-PV-01 + adjuvant and nivolumab while on this trial.

Urinary Bladder CancerBladder TumorsTransitional Cell Carcinoma of the Bladder+5 more

BioNTech US Inc.34 participantsStarted Oct 2016

Duarte, California, United States • Los Angeles, California, United States • San Francisco, California, United States +6 more locations

COMPLETEDPhase 289 miles

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

NCT02832037

The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.

Boehringer Ingelheim509 participantsStarted Jul 2016

Garden Grove, California, United States • Lemon Grove, California, United States • Orange, California, United States +78 more locations

COMPLETEDNA92 miles

Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury

NCT02660073

Spinal cord injury (SCI) is a devastating medical problem that affects thousands of civilian and military personnel in the United States. Spinal cord injuries (SCI) predispose individuals to impaired fitness, obesity, glucose intolerance and insulin resistance, placing them at greater risk for diabetes and coronary artery disease. These are devastating problems that occur frequently because of changes in body composition and reduced level of physical activity. Skeletal muscle wasting plays a central role in altered metabolism after SCI. Functional electrical stimulation (FES) is an effective rehabilitation tool that has been used to train the paralyzed skeletal muscles and which has shown some ability to ameliorate the deleterious effects of SCI on metabolism, particularly on insulin sensitivity. However, its ability to reverse skeletal muscle wasting is modest; most studies report limited gains in muscle mass and workload with highly variables outcomes from one study to another. This proposal was stimulated by the findings that a program of neuromuscular electrical stimulation resistance exercise prior to initiating functional electrical stimulation lower extremity cycling (FES-LEC) improves the gains in muscle mass and workload observed with FES. The specific objectives for the current proposal are to compare the impact of FES following evoking skeletal muscle hypertrophy of the lower extremity versus initiating FES cycling without introducing the hypertrophy effects on insulin sensitivity, control of blood sugar levels, oxygen uptake and amounts of muscle tissue and fat deposition. These studies could potentially have significant effects on thousands of people that will experience an SCI in the future as well as those living with SCI where prolonged paralysis is a major quality of life issue. There is a major need to investigate the mechanisms lead to maximize the benefits of FES applications and to understand cellular or molecular events that are associated with muscle hypertrophy and lead to promoting metabolic health after SCI. The designed study will provide a greater understanding regarding utilization of energy sources (like fats and sugars) in muscle

Spinal Cord Injuries

United States Department of Defense48 participantsStarted Oct 2015

The Bronx, New York, United States • Richmond, Virginia, United States • Richmond, Virginia, United States

COMPLETEDPhase 194 miles

NAPLS Omega-3 Fatty Acid Versus Placebo Study

NCT01429454

The overall goal of the present study is to determine whether Omega-3 Fatty Acids potentially prevent onset of psychosis and improve clinical symptoms and functional outcome in youth and young adults at elevated clinical risk for schizophrenia and related disorders. The specific aims are: (1) To determine whether the rate of progression to psychosis is lower during six months of treatment with Omega-3 Fatty Acids compared to six months of treatment with placebo, (2) To determine whether Omega-3 Fatty Acids are more efficacious than placebo for prodromal symptoms, negative symptoms, and functioning, (3) To assess the safety and tolerability of Omega-3 Fatty Acids in this population, and (4) To conduct analyses of neuroimaging, neurocognitive, electrophysiological and other ancillary data to explore mechanistic explanations for the hypothesized benefits of Omega-3 Fatty Acids on clinical and functional outcomes (e.g., increases in white matter integrity and processing speed).

University of California, San Diego127 participantsStarted Aug 2011

Los Angeles, California, United States • San Diego, California, United States • New Haven, Connecticut, United States +6 more locations

TERMINATEDPhase 2235 miles

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection

NCT02403622

The overarching objective of this study is to address the knowledge gap regarding the short-term and long-term safety of fecal microbiota transplants (FMT). The design will be a prospective, open-label, multi-center longitudinal cohort study to assess the short- and long-term safety of FMT as well as the clinical resolution of diarrhea among 150 patients with 3 or more episodes of clostridium difficile infection (CDI defined as 3 unformed stools over 24 hours for 2 consecutive days and either a positive stool test for CDI or pseudomembranes on colonoscopy/sigmoidoscopy). Subjects will be adult outpatients referred to one of the study centers after at least three recurrent episodes of CDI and previous treatment with at least one 10-day course of oral vancomycin or fidaxomicin. After FMT by colonoscopy/sigmoidoscopy or enema, patients will be followed prospectively and monitored for clinical resolution and adverse events at: 3 days (telephone), 3 weeks (clinical assessment), 8 weeks (telephone), 6 months (telephone), and 12 months (telephone) after FMT. Subjects who recur will be offered a second FMT by colonoscopy with a different donor. Microbiome analysis will be conducted from stool samples at baseline and each of the 5 follow-up intervals.

Clostridium Difficile

Microbiome Health Research Institute17 participantsStarted Mar 2015

Naperville, Illinois, United States • Indianapolis, Indiana, United States • Boston, Massachusetts, United States +1 more locations

COMPLETEDPhase 1271 miles

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

NCT03380871

The purpose of this study is to find out if treatment with NEO-PV-01 in combination with pembrolizumab and chemotherapy (pembrolizumab/chemotherapy) is safe and useful for patients with lung cancer. The study also will assess if the NEO-PV-01 vaccine, when given together with pembrolizumab and chemotherapy, can improve your response compared with pembrolizumab and chemotherapy treatment alone. All eligible patients will receive NEO-PV-01 + Adjuvant, pembrolizumab and chemotherapy while on this trial.

Carcinoma, Non-Small-Cell LungLung CancerNonsquamous Nonsmall Cell Neoplasm of Lung

BioNTech US Inc.38 participantsStarted May 2018

Santa Monica, California, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDPhase 2518 miles

Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung

NCT03157089

The main objective is to assess the efficacy of afatinib in combination with pembrolizumab, as measured by objective response (OR) in patients with locally advanced or metastatic squamous NSCLC who progressed during or after first line platinum-based treatment. The secondary objectives are to confirm the RP2D, assess the safety profile, and the secondary measures of clinical efficacy including disease control (DC), duration of objective response (DoR), progression-free survival (PFS), overall survival (OS), and tumour shrinkage.

Carcinoma, Non-Small-Cell Lung

Boehringer Ingelheim24 participantsStarted Nov 2017

Lexington, Kentucky, United States • Caen, France • Le Mans, France +10 more locations

PreviousPage 584 of 1046Next

Diabetes

in Philadelphia

Heart Diseasein Philadelphia